drugset / Trial / NCT00721669
A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
Primary objective is to evaluate the safety and PK of IMGN388
Timeline
- Start
- 2008-06
- Primary completion
- 2012-10
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMGN388 | Monoclonal antibody | — | Intravenous |